Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Taysha Gene Therapies (TSHA) Total Non-Current Liabilities: 2022-2024

Historic Total Non-Current Liabilities for Taysha Gene Therapies (TSHA) over the last 3 years, with Dec 2024 value amounting to $87.5 million.

  • Taysha Gene Therapies' Total Non-Current Liabilities rose 104.03% to $96.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $96.0 million, marking a year-over-year increase of 104.03%. This contributed to the annual value of $87.5 million for FY2024, which is 9.03% down from last year.
  • Per Taysha Gene Therapies' latest filing, its Total Non-Current Liabilities stood at $87.5 million for FY2024, which was down 9.03% from $96.2 million recorded in FY2023.
  • In the past 5 years, Taysha Gene Therapies' Total Non-Current Liabilities registered a high of $121.2 million during FY2022, and its lowest value of $87.5 million during FY2024.
  • Its 3-year average for Total Non-Current Liabilities is $101.6 million, with a median of $96.2 million in 2023.
  • Data for Taysha Gene Therapies' Total Non-Current Liabilities shows a maximum YoY fell of 20.61% (in 2023) over the last 5 years.
  • Taysha Gene Therapies' Total Non-Current Liabilities (Yearly) stood at $121.2 million in 2022, then dropped by 20.61% to $96.2 million in 2023, then declined by 9.03% to $87.5 million in 2024.